Ardelyx (ARDX) Insider Merdad Parsey Buys 39,715 Shares

On June 16, 2026, Merdad Parsey purchased 39,715 shares of Ardelyx, Inc. (NasdaqGM: ARDX). This insider transaction was not part of a pre-planned trading program.

Other Institutional Activity in Ardelyx, Inc.

Among Ardelyx's institutional investors, BlackRock, Inc. increased its holdings by 25,027 shares, reaching a total of 21,164,132 shares valued at approximately $126.8 million. Millennium Management LLC made a significant addition of 5,932,859 shares, bringing its total to 17,842,370 shares worth around $106.9 million. State Street Corp also boosted its position by 1,691,968 shares, ending with 13,604,307 shares valued at about $81.5 million. Conversely, Janus Henderson Group PLC reduced its stake by 6,143,458 shares, leaving it with 8,371,234 shares valued at $50.1 million.

Ardelyx, Inc. Stock Up 76.9%

Shares of Ardelyx, Inc. traded near $5.84. The company boasts a market capitalization of approximately $1.44 billion, with a forward P/E ratio of 11.34 and a beta of 0.576. The stock's 52-week range spans from $3.49 to $8.40, with a 50-day moving average of $6.15 and a 200-day moving average of $6.12. Ardelyx has a current ratio of 3.49, a quick ratio of 2.93, and a debt-to-equity ratio of 157.53.

Recent Earnings

Ardelyx reported revenue of $427.7 million with a growth rate of 27.5%. Despite this, the company experienced a net margin of -13.58% and a return on equity of -39.46%. The next earnings announcement is scheduled for August 3, 2026.

Insider Buying and Selling at Ardelyx, Inc.

On June 16, 2026, several insiders, including Bertrand William Jr, Richard Rodgers, Merdad Parsey, and Robert Bazemore, bought shares in Ardelyx. Bertrand William Jr and Merdad Parsey each acquired 39,715 shares, while Richard Rodgers and Robert Bazemore each purchased 26,455 shares. These transactions were not part of any pre-arranged trading plans.

Analysts Set New Price Targets

On June 16, 2026, Ladenburg Thalmann assumed coverage of Ardelyx with a 'buy' rating and a $16.00 price target. Earlier this year, HC Wainwright & Co. maintained a 'buy' rating with an $18.00 target, while Wedbush also maintained a 'buy' rating at $19.00. The consensus among analysts is a 'strong buy,' with an average target price of $16.30 based on 10 opinions.

About Ardelyx, Inc.

Ardelyx, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on discovering, developing, and commercializing treatments for unmet medical needs. The company offers IBSRELA, a therapy for irritable bowel syndrome with constipation, and XPHOZAH, a phosphate absorption inhibitor for adults with chronic kidney disease on dialysis. Founded in 2007, Ardelyx is led by CEO Michael G. Raab and employs 489 people.

Bottom Line

Merdad Parsey's recent share purchase in Ardelyx, Inc. highlights ongoing insider interest in the company. With a market cap of $1.44 billion and a strong buy consensus from analysts, Ardelyx remains a company to watch. Remember, insider transactions are reported after the fact and may not indicate future performance.